03:30 PM EST - Afexa Life Sciences Inc. : announced the encouraging results of an interim analysis performed by an independent data monitoring committee (IDMC) for the currently in-progress COLD-FX(R) clinical trial in a pediatric population. The IDMC has completed a review of the data obtained to date and unanimously recommended that the study continue into the 2011/2012 cold and flu season. Afexa Life Sciences Inc.
shares T.FXA are trading even at $0.58.
